NCT07331181招募中不适用
A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to Evaluate the Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles
Innate srl3 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2023年6月1日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 55
- 试验地点
- 3
- 主要终点
- Lemperle Rating scale
研究概览
简要总结
A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to evaluate the Performance and Safety of INNEA and INNEA AQUA for the treatment of cheek and décolletage wrinkles
详细描述
Investigational product:
INNEA and INNEA AQUA are CE-marked medical devices indicated for intradermal injections. In particular:
- INNEA is a sterile, biodegradable, isotonic, dermal filler. INNEA consists of high chain (1,0-1,5 x 106 Dalton) hyaluronic acid (HA), obtained from Streptococcus equip bacteria, formulated to a concentration of 20 mg/ml in a physiologic buffer. Each box contains one syringe of INNEA, two 30G 1⁄2" disposable sterile needles reserved for injection of INNEA and a product leaflet.
- INNEA AQUA is a sterile, biodegradable, isotonic, intradermal filler. INNEA AQUA consists of a calibrated mix of medium weight (1200 - 1500 KDalton) HA and a low weight (200 - 400 KDalton), obtained from Streptococcus equi bacteria, formulated to a concentration of 25 mg/ml in a physiologic buffer and trehalose. Each box contains one syringe of INNEA AQUA, two 30G 1⁄2" disposable sterile needles reserved for injection of INNEA AQUA and a product leaflet.
Indications:
in the physiological process of aging of the skin, the effects of which include inspissation of the horny layer (roughness and reduced radiance of the skin) and changes in the elastic fibers of the dermis (wrinkles),
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Patient Informed consent form (ICF) signed;
- •Female Subjects between 35 and 65 years old at the time of the signature of ICF;
- •Subjects with at least 2 (shallow wrinkles) on the Lemperle Rating Scale requiring correction of cheek wrinkles and/or subjects requiring correction of décolletage wrinkles;
- •Willingness to follow all study procedures, including attending all site visits, tests and examinations;
- •Agreeing to present at each study visit without make-up;
- •Willingness not to undergo other procedures involving aesthetic correction (e.g., ultrasound-based treatments, biomaterial implant, lifting, botulinum toxin injections, laser or intense pulsed light treatment, bio-stimulating treatment, chemical peeling, dermabrasion, fillers) during the entire study period;
- •Willingness to follow indications to not be exposed to make-up for 12 hours after injection;
- •Willingness to avoid prolonged exposure to sunlight and UV or using saunas or Turkish baths for one week after the injection.
排除标准
- •Other - different - clinical conditions of the skin (i.e. rosacea,psoriasis, vitiligo, active eczema, severe scleroderma, severe acne and diagnosticated cancer with/without ongoing antitumor therapy);
- •Infectious or inflammatory processes near the area of intervention;
- •Presence of naevi in the area to be injected;
- •Ongoing use or exposure to benzalkonium chloride solutions;
- •Patients who tend to develop hypertrophic scarring;
- •Patients with a history of autoimmune disease or who are receiving immune therapy;
- •Patients who are known to be hypersensitive to hyaluronic acid;
- •Presence of cutaneous disease on the tested area, as lesions, malformations and recurrent facial/labial herpes;
- •Presence of tendon, bone or muscular implants near the areaof intervention;
- •Ongoing cutaneous allergies;
- •Known hypersensitivity to cheloids;
- •Allergy or contraindications to device components;
- •Allergy or contraindication to one of the components of local anesthetic (patch or cream);
- •Immune system illnesses;
- •Diabetes mellitus or uncontrolled systemic diseases (endocrine, hepatic renal, cardiac, pulmonary, neurological disorder);
- •Problems with coagulation or undergoing anticoagulant therapy;
- •Patients who are using substances that can prolong bleeding(such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin);
- •Current treatment with anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago), drugs able to influence the test results in the investigator opinion;
- •Known drug and/or alcohol abuse;
- •Mental incapacity that precludes adequate understanding or cooperation;
- •Any previous permanent and nonpermanent cutaneous treatment for aesthetic correction (e.g., ultrasound-based treatments, biomaterial implant, lifting, botulinum toxin injections, laser or intense pulsed light treatment, bio-stimulating treatment, chemical peeling, dermabrasion, fillers) within 6 months prior to study inclusion;
- •Active malignant neoplasm of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrollment are also acceptable);
- •Pregnancy or breastfeeding;
- •COVID-19 vaccination within one month prior to study inclusion;
- •Current participation in a similar study or during the previous 3 months.
研究组 & 干预措施
Innea
Other
At visit 0 after collecting the required informations tha patients will be treat with INNEA or Innea Aqua.
Subjects can be treated in one or two of the following areas with one of the two IPs (which will be the same for the three injections planned):
- Cheek
- Décolletage Performance will be evaluated by the Investigator using the Lemperle Rating Scale (LRS) for cheek wrinkles at each visit, and the Global Aesthetic Improvement Scale (GAIS) for décolletage wrinkles at each post-treatment assessment. In addition, global aesthetic appearance of the face will be assessed through GAIS by the Investigator. Skin radiance and turgor will be evaluated by Subjects using a 5-Likert scale.
干预措施: Innea, Innea Aqua (Device)
结局指标
主要结局
Lemperle Rating scale
时间窗: 1 month after the last injections
To evaluate the performance of INNEA and INNEA AQUA for the treatment of cheek and décolletage wrinkles after 1 month from the last injection, the lamperle Rating scale will be used: \- The Lemperle Rating Scale (LRS) will be used to assess cheek wrinkles at V4 (1 month after the 3rd injection) by study product.
GAIS for improvement
时间窗: One month after the injections
The Global Aesthetic Improvement Scale (GAIS) scale will be used to assess improvement of décolletage wrinkles at V4 (1 month after the 3rd injection) by study product.
次要结局
- Outcome for performance with Lemperle Rating scale (LRS)(1 month after the last injections)
- Outcome safety: evaluation of adverse events(1 month after the last injections)
- Performance with Gais(1 month after the last injections)
- Performance with Likert scale(1 month after the last injections)
- Pain intensity evaluation with NRS scale(1 month after the last injections)
- Patience Satisfaction with Likert(1 month after the last injections)
- Evaluation of performance with Gais, secondary endpoint(1 month after the injections)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
不适用
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DMType 1 Diabetes MellitusNCT07296276i-SENS, Inc.32
尚未招募
2 期
A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy ProgressionNCT07289048Union Hospital, Tongji Medical College, Huazhong University of Science and Technology35
尚未招募
2 期
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid TumorsNCT07327411Second Affiliated Hospital of Soochow University40
Enrolling By Invitation
不适用
Persona SoluTion PPS Femur PMCFNCT07286513Zimmer Biomet200
尚未招募
2 期
Glofitamab Combined With CAR-T Therapy in R/R DLBCLNCT07326371Ruijin Hospital24